Disposables: A Solution for Efficient Biopharmaceutical Production - Disposables are growing in popularity because of the large numbers of biological drugs being developed, which require aseptic proc

ADVERTISEMENT

Disposables: A Solution for Efficient Biopharmaceutical Production
Disposables are growing in popularity because of the large numbers of biological drugs being developed, which require aseptic processes.


BioPharm International
Volume 19, Issue 7

NEW PLANT CONSTRUCTION


How Disposables Helped Hyclone Save Time and Money
Constructing a plant that incorporates disposable processing lines can shave several months off build time, during which a pharmaceutical company could potentially sell $200 million or more in drugs. Disposables require less space than conventional equipment, and they can be assembled into complete process trains offsite while the core facility is being built. These steps can reduce total construction time.

CONCLUSION

Biopharmaceutical equipment suppliers recognize that disposable processing is the paradigm of the future, and they are pouring resources into developing new single-use technologies for both upstream and downstream processes. The recent introduction of a new disposable bioreactor based on shake mixing is an example of this. On the downstream side, many single-use innovations are being unveiled in the areas of tangential flow filtration and membrane chromatography.


Quick Recap
As stand-alone disposable devices become integrated into multi-component assemblies, the time to market and cost-saving benefits increase significantly. Today's availability of disposable products is poised to turn single-use process trains into completely disposable factories.

Hélène Pora is marketing director, Pall Life Sciences, Pall France, 3 rue des Gaudines - B.P. 5253, 78175 Saint Germain-en-Laye Cedex-France, tel. +33.1.3061.32.20, fax 33.1.30.51.57.08,

REFERENCES

1. BioPlan Associates. Barre's 3rd Annual Report and Survey on BioPharmaceutical Manufacturing: Rockville, MD 2005.

2. "Outsourcing to Show Healthy Growth in Pharma."Business Communications' Pharmaceutical Contract Manufacturing and Research report cited in http://In-Pharmatechnologist.com/, March 3, 2005, http:// http://www.inpharmatechnologist.com/news/ng.asp?n=58484-outsourcing-to-show/


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International,
Click here